Activation signal transduction by proline-rich tyrosine kinase 2 (PYK2) in peripheral blood mononuclear cells from patients with systemic lupus erythematosus

Hybridoma

Volumn 28, Issue 5, 2009, Pages 333-339

  Wang, Meiying ^a   Zhang, Wei ^b   Zhang, Yuanchao ^a  

^a SHANDONG UNIVERSITY   (China)

^b QINGDAO UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 LIGAND; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FOCAL ADHESION KINASE 2; PREDNISOLONE;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CELL PROLIFERATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME BLOOD LEVEL; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SCHOOL CHILD; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD; CD40 LIGAND; CHILD; COMPLEMENT SYSTEM PROTEINS; FEMALE; FOCAL ADHESION KINASE 2; HUMANS; IMMUNOHISTOCHEMISTRY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; MONOCYTES; PHOSPHORYLATION; SIGNAL TRANSDUCTION; YOUNG ADULT;

EID: 70350462389     PISSN: 15540014     EISSN: None     Source Type: Journal    
DOI: 10.1089/hyb.2009.0023     Document Type: Article

References (40)

1. Mills JA: Systemic lupus erythematosus. N Engl J Med 1994;330:1871-1879.
2. Kotzin BL: Systemic lupus erythematosus. Cell 1996;85:303-306.
3. Dayal AK, and Kammer GM: The T cell enigma in lupus [review]. Arthritis Rheum 1996;39:23-33.
4. Juang YT, Wang Y, Solomou EE, Li Y, Mawrin C, Tenbrock K, Kyttaris VC, and Tsokos GC: Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV. J Clin Invest 2005;115:996-1005.
5. Lenschow DJ, Walunas TL, and Bluestone JA: CD28=B7 system of T cell costimulation. Annu Rev Immunol 1996;14: 233-258.
6. Pollard KM, Arnush M, Hultman P, and Kono DH: Costimulation requirements of induced murine systemic autoimmune disease. J Immunol 2004;173:5880-5887.
7. Yi Y, McNerney M, and Datta SK: Regulatory defects in Cbl and mitogen-activated protein kinase (extracellular signalrelated kinase) pathways cause persistent hyperexpression of CD40 ligand in human lupus T cells. J Immunol 2000;165: 6627-6634.
8. Koshy M, Berger D, and Crow MK: Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J Clin Invest 1996;98:826-837. (Pubitemid 26349188)
9. Wong CK, Lit LC, Tam LS, Li EK, and Lam CW: Aberrant production of soluble costimulatory molecules CTLA-4, CD28, CD80 and CD86 in patients with systemic lupus erythematosus. Rheumatology 2005;44:989-994.
10. Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G, et al.: Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003;423:506-511. (Pubitemid 36648570)
11. Mohan C, Shi Y, Laman JD, and Datta SK: Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J Immunol 1995;154:1470-1480.
12. Finck BK, Linsley PS, and Wofsy D: Treatment of murine lupus with CTLA4Ig. Science 1994;265:1225-1227.
13. Mihara M, Tan I, Chuzhin Y, Reddy B, Budhai L, Holzer A, Gu Y, and Davidson A: CTLA4Ig inhibits T cell-dependent B-cell maturation in murine systemic lupus erythematosus. J Clin Invest 2000;106:91-101.
14. Horwitz DA, Tang FL, Stimmler MM, Oki A, and Gray JD: Decreased T cell response to anti-CD2 in systemic lupus erythematosus and reversal by anti-CD28: evidence for impaired T cell-accessory cell interaction. Arthritis Rheum 1997;40:822-833.
15. Kaneko H, Saito K, Hashimoto H, Yagita H, Okumura K, and AzumaM: Preferential elimination of CD28-T cells in systemic lupus erythematosus (SLE) and the relation with activationinduced apoptosis. Clin Exp Immunol 1996;106:218-229.
16. Nakayamada S, Saito K, Nakano K, and Tanaka Y: Activation signal transduction by beta1 integrin in T cells from patients with systemic lupus erythematosus. Arthritis Rheum 2007;56:1559-1568.
17. Nakayamada S, Saito K, Fujii K, Yasuda M, Tamura M, and Tanaka Y: b1 integrin-mediated signaling induces intercellular adhesion molecule 1 and Fas on rheumatoid synovial cells and Fas-mediated apoptosis. Arthritis Rheum 2003;48:1239-1248.
18. Shahrara S, Castro-Rueda HP, Haines GK, and Koch AE: Differential expression of the FAK family kinases in rheumatoid arthritis and osteoarthritis synovial tissues. Arthritis Res Ther 2007;9:R112.
19. Regoli M, and Bendayan M: Expression of beta1 integrins in glomerular tissue of Streptozotocin-induced diabetic rats. Biochem Cell Biol 1999;77:71-78.
20. Grijelmo C, Rodrigue C, Svrcek M, Bruyneel E, Hendrix A, de Wever O, and Gespach C: Pro-invasive activity of BMP-7 through SMAD4=src-independent and ERK=Rac= JNK-dependent signaling pathways in colon cancer cells. Cell Signal 2007;19:1722-1732.
21. Xiang Y, Tan YR, Zhang JS, Qin XQ, Hu BB, Wang Y, Qu F, and Liu HJ: Wound repair and proliferation of bronchial epithelial cells regulated by CTNNAL1. J Cell Biochem 2008; 103:920-930.
22. Sasaki H, Nagura K, Ishino M, Tobioka H, Kotani K, and Sasaki T: Cloning and characterization of cell adhesion kinaseb, a novel protein-tyrosine kinase of the focal adhesion kinase subfamily. J Biol Chem 1995;270:21206-21219.
23. Lev S, Moreno H, Martinez R, Canoll P, Peles E, Musacchio JM, Plowman GD, Rudy B, and Schlessinger J: Protein tyrosine kinase PYK2 involved in Ca(2+)-induced regulation of ion channel and MAP kinase functions. Nature 1995;376: 737-745.
24. Ma EA, Lou O, Berg NN, and Ostergaard HL: Cytotoxic T lymphocytes express a beta3 integrin which can induce the phosphorylation of focal adhesion kinase and the related PYK-2. Eur J Immunol 1997;27:329-335.
25. Rodriguez-Fernandez JL, Sanchez-Martin L, Rey M, Vicente- Manzanares M, Narumiya S, Teixidó J, Sánchez-Madrid F, and Cabañas C: Rho and Rho-associated kinase modulate the tyrosine kinase PYK2 in T-cells through regulation of the activity of the integrin LFA-1. J Biol Chem 2001;276:518-540.
26. Dikic I, and Schlessinger J: Identification of a new Pyk2 isoform implicated in chemokine and antigen receptor signaling. J Biol Chem1998;273:301-308.
27. Davis CB, Dikic I, Unutmaz D, Hill CM, Arthos J, Siani MA, Thompson DA, Schlessinger J, and Littman DR: Signal transduction due to HIV-1 envelope interactions with chemokine receptors CXCR4 or CCR5. J Exp Med 1997;186: 1793-1798.
28. Ganju RK, Brubaker SA, Chernock RD, Avraham S, and Groopman JE: Beta-chemokine receptor CCR5 signals through SHP1, SHP2, and Syk. J Biol Chem 2000;275:263-268.
29. Berg NN, and Ostergaard HL: T cell receptor engagement induces tyrosine phosphorylation of FAK and Pyk2 and their association with Lck. J Immunol 1997;159:1753-1757.
30. Ganju RK, Hatch WC, Avraham H, Ona MA, Druker B, Avraham S, and Groopman JE: RAFTK, a novel member of the focal adhesion kinase family, is phosphorylated and associates with signaling molecules upon activation of mature T lymphocytes. J Exp Med 1997;185:1055-1063.
31. Qian D, Lev S, van Oers NS, Dikic I, Schlessinger J, and Weiss A: Tyrosine phosphorylation of Pyk2 is selectively regulated by Fyn during TCR signaling. J Exp Med 1997;185: 1253-1259.
32. Guinamard R, Okigaki M, Schlessinger J, and Ravetch JV: Absence of marginal zone B cells in Pyk-2-deficient mice defines their role in the humoral response. Nat Immunol 2000;1:31-36.
33. Ostergaard HL, and Lysechko TL: Focal adhesion kinaserelated protein tyrosine kinase Pyk2 in T-cell activation and function [review]. Immunol Res 2005;31:267-282.
34. Sancho D, Montoya MC, Monjas A, Gordón-Alonso M, Katagiri T, Gil D, Tejedor R, Alarcón B, and Sánchez-Madrid F: TCR engagement induces proline-rich tyrosine kinase-2 (Pyk2) translocation to the T cell-APC interface independently of Pyk2 activity and in an immunoreceptor tyrosine based activation motif-mediated fashion. J Immunol 2002; 169:292-300.
35. Gismondi A, Jacobelli J, Mainiero F, Paolini R, Piccoli M, Frati L, and Santoni A: Cutting edge: functional role for proline-rich tyrosine kinase2 in NK cell-mediated natural cytotoxicity. J Immunol 2000;164:2272-2276.
36. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Roth- field NF, Schaller JG, Talal N, and Winchester RJ: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-1277.
37. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-324.
38. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE: Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992;35:630-640.
39. Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al.: The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004;15:241-250.
40. Takagi C, Ueki K, Ikeuchi H, Kuroiwa T, Kaneko Y, Tsukada Y, Maezawa A, Mitaka T, Sasaki T, and Nojima Y: Increased expression of cell adhesion kinase beta in human and rat crescentic glomerulonephritis. Am J Kidney Dis 2002;39:174-182.